{"article":{"annotation":{"article_id":"ema-prac-october-2026-pharmacovigilance-outcomes","available_at":"2026-10-12T09:41:45.342573Z","geography_revision":"ef6ee0010dda5fe7b240fd514749b43e214c57da73222d2e40ec83b276dd0977","id":"360f1a7e38b1ffd63f964c457f1b37aad76751aca0826ffe31110b3e43e9287b","input_sha256":"67fe6f7519bf041750c9f6477bf1f919fdadb2040ea2111e73f5a89945120c52","limitations":["Rule-derived subjects are candidates, not verified editorial labels or calibrated model probabilities.","Coverage is distinct from event location. Unknown country/city/coordinates remain absent; no automatic geocoding.","Article geometries keep their stated precision and methodology; reproducing them is not independent coordinate verification."],"method":"controlled-rules-v1","places":[],"rules_sha256":"fb5ad3c27c91cb840f7a0a05f7f64a5cb26ad0374409ff9457f277c7092e22b4","schema_version":1,"subjects":[{"concept_id":"medtop:07000000","confidence":null,"confidence_method":null,"evidence":[{"field":"category+topics","language":"en","note":"Preserved editorial category/topic; broad candidate only","source_urls":["https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-28-september-1-october","https://www.ema.europa.eu/no/committees/pharmacovigilance-risk-assessment-committee-prac"]}],"method":"controlled-rules-v1","rule_id":"health-broad","status":"candidate"}],"taxonomy_revision":"1f2db31d811fca07e99b16d402c10e2cc2965c9df1c7b41d9be348b40a24e7fb","taxonomy_version":"IPTC Media Topics 2026-Q2"},"api_url":"https://newsverum.com/api/v1/articles/ema-prac-october-2026-pharmacovigilance-outcomes?lang=es","category":"health","content":{"key_points":[],"paragraphs":["El Comité para la Evaluación de Riesgos en Farmacovigilancia (PRAC) de la Agencia Europea de Medicamentos publicó las cifras de octubre tras su reunión del 28 de septiembre al 1 de octubre. El resumen registra 85 evaluaciones únicas de informes periódicos de actualización de seguridad, 49 planes de gestión de riesgos de medicamentos autorizados de forma centralizada y 16 estudios posteriores a la autorización.","El comité comunicó nueve señales de seguridad: cinco se iniciaron y cuatro estaban en curso o concluidas. La EMA indicó que durante la reunión no se inició ni concluyó ningún procedimiento de remisión. Estas cifras no demuestran que un medicamento causara daño ni que se impusiera una restricción nueva.","La agencia señala que las estadísticas se basan en el proyecto de orden del día. Una señal puede indicar una asociación entre un medicamento y un evento que requiere investigación; por sí sola no prueba causalidad."],"sections":[]},"corrections":[{"at":"2026-10-07T00:56:16+03:00","language":"es","text":"Se añadieron a este artículo las ediciones alemana y portuguesa y las traducciones de las explicaciones de datos y correcciones."},{"at":"2026-10-12T06:19:32+03:00","language":"es","text":"Se corrigió la redacción de las traducciones de las etiquetas o explicaciones de los datos."}],"country":null,"data":{"blocks":[{"description":{"ar":"أعداد التقييمات الشهرية استناداً إلى جدول الأعمال الأولي.","de":"Monatliche Bewertungszahlen auf Grundlage des Entwurfs der Tagesordnung.","en":"Monthly assessment counts based on the draft agenda.","es":"Recuentos mensuales de evaluaciones según el proyecto de orden del día.","fr":"Nombre mensuel d’évaluations selon le projet d’ordre du jour.","pt":"Contagens mensais de avaliações com base na pauta preliminar.","tr":"Taslak gündeme dayalı aylık değerlendirme sayıları."},"id":"verified-indicators","items":[{"basis":"observed","label":{"ar":"إشارات السلامة","de":"Sicherheitssignale","en":"Safety signals","es":"Señales de seguridad","fr":"Signaux de sécurité","pt":"Sinais de segurança","tr":"Güvenlik sinyalleri"},"measure":{"aggregation":"flow","frequency":"monthly","geography":"european-union","id":"prac-safety-signals","periodRole":"announcement-date","unitCode":"count"},"period":"2026-10","unit":"count","value":9},{"basis":"observed","label":{"ar":"التقييمات المنفردة لتقارير PSUR","de":"Einzelbewertungen von PSUR","en":"PSUR single assessments","es":"Evaluaciones únicas de PSUR","fr":"Évaluations uniques de PSUR","pt":"Avaliações individuais de PSUR","tr":"PSUR tekil değerlendirmeleri"},"measure":{"aggregation":"flow","frequency":"monthly","geography":"european-union","id":"prac-psur-single-assessments","periodRole":"announcement-date","unitCode":"count"},"period":"2026-10","unit":"count","value":85},{"basis":"observed","label":{"ar":"خطط إدارة مخاطر الأدوية المرخصة مركزياً","de":"Risikomanagementpläne für zentral zugelassene Arzneimittel","en":"Risk-management plans for centrally authorised medicines","es":"Planes de gestión de riesgos para medicamentos autorizados mediante procedimiento centralizado","fr":"Plans de gestion des risques pour les médicaments autorisés par procédure centralisée","pt":"Planos de gerenciamento de riscos para medicamentos autorizados por procedimento centralizado","tr":"Merkezi ruhsatlı ilaçlar için risk yönetim planları"},"measure":{"aggregation":"flow","frequency":"monthly","geography":"european-union","id":"prac-central-risk-plans","periodRole":"announcement-date","unitCode":"count"},"period":"2026-10","unit":"count","value":49},{"basis":"observed","label":{"ar":"دراسات السلامة بعد الترخيص","de":"Sicherheitsstudien nach der Zulassung","en":"Post-authorisation safety studies","es":"Estudios de seguridad posteriores a la autorización","fr":"Études de sécurité post-autorisation","pt":"Estudos de segurança pós-autorização","tr":"Ruhsat sonrası güvenlilik çalışmaları"},"measure":{"aggregation":"flow","frequency":"monthly","geography":"european-union","id":"prac-post-authorisation-safety-studies","periodRole":"announcement-date","unitCode":"count"},"period":"2026-10","unit":"count","value":16},{"basis":"observed","label":{"ar":"إجراءات الإحالة التي بدأت أو استمرت أو اختُتمت","de":"Begonnene, laufende oder abgeschlossene Befassungsverfahren","en":"Referrals started, ongoing or concluded","es":"Remisiones iniciadas, en curso o concluidas","fr":"Saisines commencées, en cours ou conclues","pt":"Procedimentos de encaminhamento iniciados, em andamento ou concluídos","tr":"Başlatılan, süren veya sonuçlanan sevk prosedürleri"},"measure":{"aggregation":"flow","frequency":"monthly","geography":"european-union","id":"prac-referral-procedures","periodRole":"announcement-date","unitCode":"count"},"period":"2026-10","unit":"count","value":0}],"methodology":{"ar":"إشارة السلامة ليست دليلاً على السببية؛ وجميع الأعداد مبنية على جدول الأعمال الأولي.","de":"Ein Sicherheitssignal beweist keine Ursache; alle Zahlen beruhen auf dem Entwurf der Tagesordnung.","en":"A safety signal is not proof of causation; all counts are based on the draft agenda.","es":"Una señal de seguridad no prueba causalidad; todos los recuentos se basan en el proyecto del orden del día.","fr":"Un signal de sécurité ne prouve pas la causalité ; tous les chiffres reposent sur le projet d’ordre du jour.","pt":"Um sinal de segurança não comprova causalidade; todas as contagens se baseiam na pauta preliminar.","tr":"Güvenlik sinyali nedensellik kanıtı değildir; tüm sayılar taslak gündem temellidir."},"sourceUrls":["https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-28-september-1-october"],"title":{"ar":"إحصاءات لجنة PRAC في أكتوبر","de":"PRAC-Statistik für Oktober","en":"PRAC October statistics","es":"Estadísticas de octubre del PRAC","fr":"Statistiques d’octobre du PRAC","pt":"Estatísticas do PRAC em outubro","tr":"PRAC ekim istatistikleri"},"type":"metrics","updatedAt":"2026-10-12T06:19:32+03:00"}],"version":1},"data_downloads":[{"formats":{"csv":"https://newsverum.com/api/v1/articles/ema-prac-october-2026-pharmacovigilance-outcomes/data/verified-indicators?lang=es&format=csv","json":"https://newsverum.com/api/v1/articles/ema-prac-october-2026-pharmacovigilance-outcomes/data/verified-indicators?lang=es&format=json"},"id":"verified-indicators"}],"data_types":["metrics"],"editorial_illustration":{"alt":"Ilustración conceptual de salud pública, investigación y datos conectados.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"es","scope":"topic","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"event_id":"event-4e22bbce-1bd4-5a4f-adf7-eedfd2dca91c","event_period":"2026-10-02","event_period_basis":"event-or-reference-period","id":"ema-prac-october-2026-pharmacovigilance-outcomes","image":null,"importance":0.6,"language":"es","modified_at":"2026-10-12T06:19:32+03:00","publication_basis":"publication-record","published_at":"2026-10-04T01:05:40+00:00","reading_minutes":2,"region":"world","relations":[],"section_illustration":{"alt":"Ilustración conceptual de salud pública, investigación y datos conectados.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"es","scope":"section","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"slug":"ema-prac-october-2026-pharmacovigilance-outcomes","sources":[{"checkedAt":"2026-10-04","name":"European Medicines Agency","publishedAt":"2026-10-02","url":"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-28-september-1-october"},{"checkedAt":"2026-10-04","name":"European Medicines Agency PRAC committee calendar","url":"https://www.ema.europa.eu/no/committees/pharmacovigilance-risk-assessment-committee-prac"}],"summary":"Las cifras mensuales del PRAC registran nueve señales de seguridad, 49 planes de riesgos y 16 estudios posteriores a la autorización.","text":"Las cifras mensuales del PRAC registran nueve señales de seguridad, 49 planes de riesgos y 16 estudios posteriores a la autorización.\n\nEl Comité para la Evaluación de Riesgos en Farmacovigilancia (PRAC) de la Agencia Europea de Medicamentos publicó las cifras de octubre tras su reunión del 28 de septiembre al 1 de octubre. El resumen registra 85 evaluaciones únicas de informes periódicos de actualización de seguridad, 49 planes de gestión de riesgos de medicamentos autorizados de forma centralizada y 16 estudios posteriores a la autorización.\n\nEl comité comunicó nueve señales de seguridad: cinco se iniciaron y cuatro estaban en curso o concluidas. La EMA indicó que durante la reunión no se inició ni concluyó ningún procedimiento de remisión. Estas cifras no demuestran que un medicamento causara daño ni que se impusiera una restricción nueva.\n\nLa agencia señala que las estadísticas se basan en el proyecto de orden del día. Una señal puede indicar una asociación entre un medicamento y un evento que requiere investigación; por sí sola no prueba causalidad.\n\nSe añadieron a este artículo las ediciones alemana y portuguesa y las traducciones de las explicaciones de datos y correcciones.\n\nSe corrigió la redacción de las traducciones de las etiquetas o explicaciones de los datos.","title":"El comité de seguridad de la EMA evaluó 85 informes de medicamentos en octubre","topics":[],"translations":[{"api_url":"https://newsverum.com/api/v1/articles/ema-prac-october-2026-pharmacovigilance-outcomes?lang=tr","language":"tr","url":"https://newsverum.com/tr/news/ema-prac-october-2026-pharmacovigilance-outcomes"},{"api_url":"https://newsverum.com/api/v1/articles/ema-prac-october-2026-pharmacovigilance-outcomes?lang=en","language":"en","url":"https://newsverum.com/en/news/ema-prac-october-2026-pharmacovigilance-outcomes"},{"api_url":"https://newsverum.com/api/v1/articles/ema-prac-october-2026-pharmacovigilance-outcomes?lang=ar","language":"ar","url":"https://newsverum.com/ar/news/ema-prac-october-2026-pharmacovigilance-outcomes"},{"api_url":"https://newsverum.com/api/v1/articles/ema-prac-october-2026-pharmacovigilance-outcomes?lang=fr","language":"fr","url":"https://newsverum.com/fr/news/ema-prac-october-2026-pharmacovigilance-outcomes"},{"api_url":"https://newsverum.com/api/v1/articles/ema-prac-october-2026-pharmacovigilance-outcomes?lang=es","language":"es","url":"https://newsverum.com/es/news/ema-prac-october-2026-pharmacovigilance-outcomes"},{"api_url":"https://newsverum.com/api/v1/articles/ema-prac-october-2026-pharmacovigilance-outcomes?lang=de","language":"de","url":"https://newsverum.com/de/news/ema-prac-october-2026-pharmacovigilance-outcomes"},{"api_url":"https://newsverum.com/api/v1/articles/ema-prac-october-2026-pharmacovigilance-outcomes?lang=pt","language":"pt","url":"https://newsverum.com/pt/news/ema-prac-october-2026-pharmacovigilance-outcomes"}],"url":"https://newsverum.com/es/news/ema-prac-october-2026-pharmacovigilance-outcomes"},"version":"1"}
